ArticleEuropean urology open science2026
Treatment Persistence and Adherence with Overactive Bladder Medications in Taiwan: A Retrospective Database Analysis.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Overactive bladder (OAB) is commonly treated with mirabegron or antimuscarinics, but real-world evidence on treatment persistence, adherence, and fall/fracture outcomes in Taiwan remains limited. Objective: To assess treatment persistence, adherence, and associated outcome rates of falls/fractures, in patients receiving OAB treatment with mirabegron or antimuscarinics in Taiwan. Design setting and participants: Retrospective, longitudinal, observational study of routine clinical practice within the Taiwanese National Health Insurance Research Database. Eligibility: age ≥20 years; ≥1 dispensing for a new OAB index drug (January 1, 2012 to December 31, 2018); continuous enrollment 1 year before and after index prescription date. Intervention: OAB Treatment with mirabegron or antimuscarinics. Outcome measurements and statistical analysis: Primary endpoint: treatment persistence (time to discontinuation [TTD] or switch) and adherence (proportion of days covered [PDC]); secondary endpoint: incidence of falls/fractures. Multivariate Cox proportional hazards analyses were applied to estimate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs), describing associations between treatment groups and outcomes. Results and limitations: Overall, 1,954,544 patients were eligible (median age 60 years). Median (interquartile range [IQR]) TTD was longer with mirabegron (56 [19-168] days) than antimuscarinics (14 [5-42] days) (risk of discontinuation aHR 1.58 [95% CI 1.55-1.61]; p < 0.001). Median (IQR) PDC was significantly higher with mirabegron (0.18 [0.06-0.52]) than antimuscarinics (0.03 [0.01-0.12]; p < 0.001). Mirabegron and antimuscarinics had no statistically significant difference in the risk of composite falls/fractures (aHR 1.05 [95% CI 0.91-1.20]; p = 0.519), falls (1.33 [0.66-2.68]; p = 0.431), and fractures (1.04 [0.90-1.19]; p = 0.623). Conclusions: Persistence and adherence were significantly greater with mirabegron than antimuscarinics in patients receiving OAB treatment in Taiwan. No statistically significant association was observed for the incidence of falls/fractures between treatment groups. However, given the wide 95% CIs, the findings should not be interpreted as equivalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.